MiMedx Group (NASDAQ:MDXG – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.
Several other brokerages have also recently weighed in on MDXG. Mizuho set a $7.00 price target on MiMedx Group in a research report on Thursday, October 29th. Seaport Research Partners cut MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 price objective on shares of MiMedx Group in a report on Tuesday. Weiss Ratings downgraded MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, October 29th. Finally, Craig Hallum lifted their target price on MiMedx Group from $6.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.14.
Check Out Our Latest Stock Analysis on MiMedx Group
MiMedx Group Trading Down 1.8%
MiMedx Group (NASDAQ:MDXG – Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $62.28 million for the quarter, compared to analysts’ expectations of $68.56 million. MiMedx Group had a positive return on equity of 2.39% and a negative net margin of 6.32%. On average, equities research analysts forecast that MiMedx Group will post -0.08 EPS for the current year.
Institutional Trading of MiMedx Group
Several institutional investors and hedge funds have recently bought and sold shares of MDXG. American Century Companies Inc. boosted its holdings in MiMedx Group by 253.1% in the third quarter. American Century Companies Inc. now owns 1,901,087 shares of the company’s stock valued at $8,859,000 after acquiring an additional 1,362,695 shares in the last quarter. Allworth Financial LP raised its holdings in MiMedx Group by 59.7% in the 3rd quarter. Allworth Financial LP now owns 10,032 shares of the company’s stock worth $47,000 after purchasing an additional 3,751 shares in the last quarter. Private Capital Management LLC raised its holdings in MiMedx Group by 886.2% in the 3rd quarter. Private Capital Management LLC now owns 193,206 shares of the company’s stock worth $900,000 after purchasing an additional 173,615 shares in the last quarter. Aquatic Capital Management LLC raised its holdings in MiMedx Group by 365.6% in the 3rd quarter. Aquatic Capital Management LLC now owns 23,923 shares of the company’s stock worth $111,000 after purchasing an additional 18,785 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of MiMedx Group by 15.5% in the 3rd quarter. Cetera Investment Advisers now owns 56,420 shares of the company’s stock worth $263,000 after purchasing an additional 7,568 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
MiMedx Group Company Profile
MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company’s products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.
Featured Articles
- Five stocks we like better than MiMedx Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
